John Dawson awarded CBE in New Year Honours List

RNS Number : 2523X

Oxford Biomedica PLC

04 January 2022

 

John Dawson awarded CBE in the Queen's New Year Honours List  

Oxford, UK - 4 January 2022:  Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, is pleased to announce that the Group's Chief Executive Officer John Dawson has been awarded a CBE (Commander of the Order of the British Empire) for services to UK Life Science as part of the Queen's New Year Honours List .

Dr. Roch Doliveux, Chair of Oxford Biomedica, said : " I warmly congratulate John for receiving this thoroughly deserved recognition. Thanks to his foresight, Oxford Biomedica has grown to become a world leader in cell and gene therapy, helping society during the COVID-19 pandemic and beyond. I and the entire Board are extremely grateful to John for his warm and resilient leadership and having built Oxford Biomedica as a world leader in viral vectors for cell and gene therapy, enabling so many lives to be saved."

-Ends-

Enquiries: 

Oxford Biomedica plc: T: [phone] / E: [e-mail]

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications: T: [phone]

Mary-Jane Elliott / Matthew Neal  

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim and Arcellx, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com  

 

END

 

 

NRAUPUUCGUPPPGW